Advertisement

Japanese Journal of Ophthalmology

, Volume 63, Issue 1, pp 90–99 | Cite as

Correlation between macular structure and function in patients with age-related macular degeneration treated with intravitreal ranibizumab: 12-month-results

  • Tomoharu Nishimura
  • Shigeki MachidaEmail author
Clinical Investigation
  • 59 Downloads

Abstract

Purpose

To determine the significance of the correlation between optical coherence tomographic (OCT) findings and focal macular electroretinograms (fmERG) at 12 months after beginning intravitreal injections of ranibizumab (IVR) in eyes with age-related macular degeneration (AMD).

Study design

Prospective, clinical study.

Method

We studied 28 eyes of 28 patients with AMD treated with IVR at monthly intervals for the initial three months. Additional IVR was given according to a pro re nata (PRN) regimen. OCT and fmERGs were performed preoperatively and at 3 and 12 months postoperatively. The fmERGs were elicited by a 15° white stimulus spot centered on the fovea. The thickness of the inner, middle, and outer layers of the retina and also of the serous retinal detachment (SRD) and pigment epithelial detachment (PED) in the horizontal and vertical meridians at 1.2 mm from the fovea (parafoveal) were measured in the OCT images.

Results

The b-wave amplitude at 12 months was significantly correlated with the thicknesses of the outer retinal layer, SRD, and PED (P=0.001–0.02). Multiple regression analyses showed that the outer retinal layer thickness was an independent determinant (P= 0.0001). The changes in the b-wave amplitude between the baseline and 12 months were significantly correlated with the changes in the SRD thickness (P=0.006). The changes in the b-wave amplitude during the PRN period were significantly correlated with the changes in the PED thickness (P=0.02).

Conclusions

At 12 months after beginning treatment, the reduction in the SRD thickness affects macular function recovery. As recurrences of the PED can occur during the PRN period, control of the PED is necessary to obtain good macular function for the long term.

Keywords

Age-related macular degeneration Intravitreal ranibizumab Focal macular electroretinogram Serous retinal detachment Pigment epithelial detachment 

Notes

Conflicts of interest

T. Nishimura, None; S. Machida, None.

References

  1. 1.
    Oshima Y, Ishibashi T, Murata T, Tahara Y, Kiyohara Y, Kubota T. Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study. Br J Ophthalmol. 2001;85:1153–7.CrossRefGoogle Scholar
  2. 2.
    Yasuda M, Kiyohara Y, Hata Y, Arakawa S, Yonemoto K, Doi Y, et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. Ophthalmology. 2009;116:2135-40.CrossRefGoogle Scholar
  3. 3.
    Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, MARINA study group, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.CrossRefGoogle Scholar
  4. 4.
    Brown DM, Kaiser PK, Michels M, Michels M, Soubrane G, Heier JS, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.CrossRefGoogle Scholar
  5. 5.
    Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Lanchulev T, ANCHOR study group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57–65.CrossRefGoogle Scholar
  6. 6.
    Johnston RL, Lee AY, Buckle M, Antcliff R, Bailey C, McKibbin M, UK AMD EMR Users Group, et al. UK age-related macular degeneration electronic medical record system (AMD EMR) users group report IV: incidence of blindness and sight impairment in ranibizumab-treated patients. Ophthalmology. 2016;123:2386–92.CrossRefGoogle Scholar
  7. 7.
    Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. VIEW 1 and VIEW 2 study groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.CrossRefGoogle Scholar
  8. 8.
    Ogura Y, Terasaki H, Gomi F, Yuzawa M, Iida T, Honda M, et al. VIEW 2 investigators efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. Br J Ophthalmol. 2015;99:92–7.CrossRefGoogle Scholar
  9. 9.
    Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98.CrossRefGoogle Scholar
  10. 10.
    Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124:1296–304.CrossRefGoogle Scholar
  11. 11.
    Yuzawa M, Fujita K, Wittrup-Jensen KU, Norenberg C, Zeitz O, Adachi K, et al. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration. Ophthalmology. 2015;122:571–8.CrossRefGoogle Scholar
  12. 12.
    Nishihara H, Kondo M, Ishikawa K, Sugita T, Pia CH, Nakamura Y, et al. Focal macular electroretinograms in eyes with wet-type age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:3121–5.CrossRefGoogle Scholar
  13. 13.
    Iwata E, Ueno S, Ishikawa K, Ito Y, Uetani R, PIao CH, et al. Focal macular electroretinograms after intravitreal injections of bevacizumab for age-related macular degeneration. Invest Ophthamol Vis Sci. 2012;53:4185–90.CrossRefGoogle Scholar
  14. 14.
    Nishimura T, Machida S, Harada T, Kurosaka D. Retinal ganglion cell function after repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration. Clin Ophthalmol. 2012;6:1073–82.Google Scholar
  15. 15.
    Ogino K, Tsujikawa A, Yamashiro K, Ooto S, Oishi A, Nakata I, et al. Intravitreal injection of ranibizumab for recovery of macular function in eyes with subfoveal polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2013;54:3771–9.CrossRefGoogle Scholar
  16. 16.
    Takayama K, Kaneko H, Ueno S, Maruko R, Piao CH, Yasuda S, et al. Evaluation of short-term outcomes of intravitreal aflibercept injections for age-related macular degeneration using focal macular electroretinography. Retina. 2017;37:553–60.CrossRefGoogle Scholar
  17. 17.
    Miyake Y, Yanagida K, Kondo K, Ota I. Subjective scotometry and recording of local electroretinogram and visual evoked response. System with television monitor of the fundus. Jpn J Ophthalmol. 1981;25:439–48.Google Scholar
  18. 18.
    Miyake Y. Studies of local macular ERG. Acta Soc Ophthalmol Jpn. 1988;92:1419–49.Google Scholar
  19. 19.
    Nishimura T, Machida S, Hashizume K, Kurosaka D. Structures affecting recovery of macular function in patients with age-related macular degeneration after intravitreal ranibizumab. Graefe´s Arch Clin Exp Ophthalmol. 2015;253:1201–9.CrossRefGoogle Scholar
  20. 20.
    Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43–58.CrossRefGoogle Scholar
  21. 21.
    Hibi N, Ueno S, Ito Y, Piao CH, Kondo M, Terasaki H. Relationship between retinal layer thickness and focal macular electroretinogram components after epiretinal membrane surgery. Invest Ophthalmol Vis Sci. 2013;54:7207–14.CrossRefGoogle Scholar
  22. 22.
    Machida S, Toba Y, Ohtaki A, Gotoh Y, Kaneko M, Kurosaka D. Photopic negative response of focal electroretinogram in glaucomatous eyes. Invest Ophthalmol Vis Sci. 2008;49:5636–44.CrossRefGoogle Scholar
  23. 23.
    Tamada K, Machida S, Oikawa T, Miyamoto H, Nishimura T, Kurosaka D. Correlation between photopic negative response of focal electroretinograms and local loss of retinal neurons in glaucoma. Curr Eye Res. 2010;35:155–64.CrossRefGoogle Scholar
  24. 24.
    Kizawa J, Machida S, Kobayashi T, Gotoh Y, Kurosaka D. Changes of oscillatory potentials and photopic negative response in patients with early diabetic retinopathy. Jpn J Ophthalmol. 2006;50:367–73.CrossRefGoogle Scholar
  25. 25.
    Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Comparison of Age-related Macular Degeneration Treatments Trials Research Group, et al. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:865–75.CrossRefGoogle Scholar
  26. 26.
    Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014;121:1237–45.CrossRefGoogle Scholar
  27. 27.
    Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA CA, CATT Research Group, et al. Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150–61.CrossRefGoogle Scholar
  28. 28.
    Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, Comparison of Age-related Macular Degeneration Treatments Trials Research Group, et al. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:656–66.CrossRefGoogle Scholar
  29. 29.
    Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122:822–32.CrossRefGoogle Scholar
  30. 30.
    Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol. 2014;252:647–55.CrossRefGoogle Scholar
  31. 31.
    Giansanti F, Bacherini D, Giacomelli G, Virgili G, Finocchio L, Fiore T, et al. Intravitreal anti-VEGF therapy for vascularized pigment epithelium detachment in age-related macular degeneration. Eur J Ophthalmol. 2014;24:402–8.CrossRefGoogle Scholar
  32. 32.
    Essex RW, Nguyen V, Walton R, Arnold JJ, McAllister IL, Guymer RH, Fight Retinal Blindness Study Group, et al. Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration. Ophthalmology. 2016;123:2393–400.CrossRefGoogle Scholar
  33. 33.
    Balaskas K, Karampelas M, Horani M, Hotu O, Keane P, Aslam T. Quantitative analysis of pigment epithelial detachment response to different anti-vascular endothelial growth factor agents in wet age-related macular degeneration. Retina. 2017;37:1297–304.CrossRefGoogle Scholar
  34. 34.
    Cho HJ, Kim KM, Kim HS, Lee DW, Kim CG, Kim JW. Response of pigment epithelial detachment to anti-vascular endothelial growth factor treatment in age-related macular degeneration. Am J Ophthalmol. 2016;166:112–9.CrossRefGoogle Scholar
  35. 35.
    Yun C, Oh J, Ahn J, Hwang SY, Lee B, Kim SW, et al. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2016;254:1693–702.CrossRefGoogle Scholar
  36. 36.
    Zinkernagel MS, Wolf S, Ebneter A. Fluctuations in pigment epithelial detachment and retinal fluid using a bimonthly treatment regimen with aflibercept for neovascular age-related macular degeneration. Ophthalmologica. 2016;235:42–8.CrossRefGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2018

Authors and Affiliations

  1. 1.Department of OphthalmologyDokkyo Medical University Saitama Medical CenterKoshigayaJapan
  2. 2.Department of OphthalmologyIwate Medical University School of MedicineMoriokaJapan

Personalised recommendations